CRGX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -0.3%, SMA50 0.36%, SMA200 -43.4%). The stock’s 14-day RSI is 49.32 (neutral), while the ATR of 0.07 points to moderate volatility. The stock remains hovering near 52-week lows, trading -82.44% below its high and over 49.0% above its low.

CARGO Therapeutics, Inc. Common Stock has 48.36 million shares outstanding. The public float is 30.04 million shares, elevated short interest at 7.55% of float. This equals 3.04 million shares. The short ratio is 1.08 days. Institutional investors hold 99.91% of the float. Insiders own 0.63%. PERCEPTIVE ADVISORS LLC holds 333.33 thousand shares, Radhakrishnan Anup has 120.78 thousand shares and Chapman Gina has 103.90 thousand shares.

Wall Street analysts project EPS growth of 32.19% annually over the next five years. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 11.86% upside. The low target suggests 11.86% downside. The mean target is $5.00. This offers 11.86% upside. CARGO Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended August 06, 2025, missed forecasts by -28.95%. The prior quarter beat by 14.29%. Over the last six quarters, Apple has recorded several small beats. These include -17.14% in May 14, 2024.

CARGO Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.78. This means the shares are trading above this model’s fair value.

CARGO Therapeutics, Inc. Common Stock (NASDAQ:CRGX) shares are down -69.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CARGO Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.97. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $21.70, suggesting 385.46% upside. Our AI forecast model points to short-term weakness (-0.45% over two weeks), a medium-term rise (6.71% over three months), and a longer-term gain (385.68% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that CARGO Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.45%, with price expected at $4.45 by September 01, 2025, within a range of $4.35 to $4.54 3-Month Outlook: Projected rise of 6.71%, reaching $4.77 by November 14, 2025, with a range of $3.77 to $5.46. 1-Year Outlook: Projected gain of 385.68%, with price at $21.71 by August 18, 2026, within a range of $21.79 to $26.46.

The stock is currently mid-range between its 52-week high and low $3.00 and $25.45. With a market capitalization of about $216.19 million, CARGO Therapeutics, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.29). Key stats such as the average daily volume over the past year has been around 1.68 million shares, trading with heavier-than-usual volume. Headquartered in San Mateo, DE, CARGO Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Anup Radhakrishnan, the company employs approximately 167 people and listed since November 13, 2023. CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.

CARGO Therapeutics, Inc. Common Stock trades at a P/E ratio of -0.97, slightly below the S&P 500 average, with a price-to-sales ratio of 27.61 and a price-to-book ratio of 0.91 suggesting the stock is closer to book value. The P/FCF stands at -1.12, also above market averages.